Skip to main content
SpringerLink
Log in

Membranous Nephropathy

  • Chapter
  • First Online:
Book cover Core Concepts in Parenchymal Kidney Disease

  • 1342 Accesses

Abstract

Primary membranous nephropathy is the most common form of nephrotic syndrome in Caucasian adults and a frequent cause of end-stage renal disease. It is characterized by sub-epithelial immune deposits and is the prototype of an autoimmune glomerular disease. Clinical course is variable and up to 30 % of patients may go into spontaneous remission. The discovery of two major podocytes antigens: neutral endopeptidase (NEP), involved in rare cases of neonatal MN, and the M-type phospholipase–A2 receptor 1 (PLA2R1) the first antigen discovered in adults, have been major “breakthroughs” in our understanding of the pathogenesis of human MN. The presence of circulating antibodies against bovine serum album in some children with membranous nephropathy raises the possibility that food antigens may also be involved in its pathogenesis. Genetic susceptibility studies have linked single-nucleotide polymorphisms (SNPs) in the genes encoding M-type phospholipase A2 receptor 1 (PLA2R) and HLA complex class II HLA-DQ alpha chain 1 (HLA-DQA1) in Caucasian populations with membranous nephropathy. Current therapies include combined use of corticosteroids and alkylating agents, or calcineurin inhibitors. The first treatment may favor remission and protect renal function but may be associated with significant adverse effects. Calcineurin inhibitors may reduce proteinuria but have a high relapse rate. New therapies have being sought with the use of adrenocorticotropic hormone and rituximab. Further research may facilitate a more patient-specific treatment approach in these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Medawar W, Green A, Campbell E, et al. Clinical and histopathologic findings in adults with the nephrotic syndrome. Ir J Med Sci. 1990;159:137–40.

    PubMed  CAS  Google Scholar 

  2. Beck Jr LH, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361:11–21.

    PubMed  CAS  Google Scholar 

  3. Stanescu HC, Arcos-Burgos M, Medlar A, et al. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med. 2011;364:616–26.

    PubMed  CAS  Google Scholar 

  4. Ruggenenti P, Chiurchiu C, Brusegan V, et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol. 2003;14:1851–7.

    PubMed  CAS  Google Scholar 

  5. Fervenza FC, Sethi S, Specks U. Idiopathic membranous nephropathy: diagnosis and treatment. Clin J Am Soc Nephrol. 2008;3:905–19.

    PubMed  Google Scholar 

  6. Ponticelli C, Passerini P. Management of idiopathic membranous nephropathy. Expert Opin Pharmacother. 2010;11:2163–75.

    PubMed  CAS  Google Scholar 

  7. Kerjaschki D, Farquhar MG. The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc Natl Acad Sci USA. 1982;79:5557–61.

    PubMed  CAS  Google Scholar 

  8. Kerjaschki D, Farquhar MG. Immunocytochemical localization of the Heymann nephritis antigen (GP330) in glomerular epithelial cells of normal Lewis rats. J Exp Med. 1983;157:667–86.

    PubMed  CAS  Google Scholar 

  9. Herrmann SM, Sethi S, Fervenza FC. Membranous nephropathy: the start of a paradigm shift. Curr Opin Nephrol Hypertens. 2012;21:203–10.

    PubMed  CAS  Google Scholar 

  10. Glassock RJ. The pathogenesis of membranous nephropathy: evolution and revolution. Curr Opin Nephrol Hypertens. 2012;21(3):235–42.

    PubMed  CAS  Google Scholar 

  11. Debiec H, Guigonis V, Mougenot B, et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med. 2002;346:2053–60.

    PubMed  Google Scholar 

  12. Debiec H, Nauta J, Coulet F, et al. Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet. 2004;364:1252–9.

    PubMed  CAS  Google Scholar 

  13. Ronco P, Debiec H. Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy. J Am Soc Nephrol. 2010;21:564–9.

    PubMed  CAS  Google Scholar 

  14. Llorca O. Extended and bent conformations of the mannose receptor family. Cell Mol Life Sci. 2008;65:1302–10.

    PubMed  CAS  Google Scholar 

  15. Hofstra JM, Beck Jr LH, Beck DM, et al. Anti-phospholipase A receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2011;6:1286–91.

    PubMed  CAS  Google Scholar 

  16. Qin W, Beck Jr LH, Zeng C, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol. 2011;22:1137–43.

    PubMed  CAS  Google Scholar 

  17. Beck Jr LH, Fervenza FC, Beck DM, et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol. 2011;22:1543–50.

    PubMed  CAS  Google Scholar 

  18. Debiec H, Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med. 2011;364:689–90.

    PubMed  CAS  Google Scholar 

  19. Prunotto M, Carnevali ML, Candiano G, et al. Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol. 2010;21:507–19.

    PubMed  CAS  Google Scholar 

  20. Murtas C, Ravani P, Ghiggeri GM. New insights into membranous glomerulonephritis: from bench to bedside. Nephrol Dial Transplant. 2011;26:2428–30.

    PubMed  Google Scholar 

  21. Bruschi M, Carnevali ML, Murtas C, et al. Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: Alfa-enolase and borderline antigens. J Proteomics. 2011;74:2008–17.

    PubMed  CAS  Google Scholar 

  22. Wakui H, Imai H, Komatsuda A, et al. Circulating antibodies against alpha-enolase in patients with primary membranous nephropathy (MN). Clin Exp Immunol. 1999;118:445–50.

    PubMed  CAS  Google Scholar 

  23. Hill GS. Tubulointerstitial nephritis and vasculitis. Curr Opin Nephrol Hypertens. 1994;3:356–63.

    PubMed  CAS  Google Scholar 

  24. Moodie FD, Leaker B, Cambridge G, et al. Alpha-enolase: a novel cytosolic autoantigen in ANCA positive vasculitis. Kidney Int. 1993;43:675–81.

    PubMed  CAS  Google Scholar 

  25. Pratesi F, Moscato S, Sabbatini A, et al. Autoantibodies specific for alpha-enolase in systemic autoimmune disorders. J Rheumatol. 2000;27:109–15.

    PubMed  CAS  Google Scholar 

  26. Roozendaal C, de Jong MA, van den Berg AP, et al. Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases. J Hepatol. 2000;32:734–41.

    PubMed  CAS  Google Scholar 

  27. Vermeulen N, Vermeire S, Arijs I, et al. Seroreactivity against glycolytic enzymes in inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:557–64.

    PubMed  Google Scholar 

  28. Debiec H, Lefeu F, Kemper MJ, et al. Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med. 2011;364:2101–10.

    PubMed  CAS  Google Scholar 

  29. Mogues T, Li J, Coburn J, et al. IgG antibodies against bovine serum albumin in humans—their prevalence and response to exposure to bovine serum albumin. J Immunol Methods. 2005;300:1–11.

    PubMed  CAS  Google Scholar 

  30. Adler SG, Wang H, Ward HJ, et al. Electrical charge. Its role in the pathogenesis and prevention of experimental membranous nephropathy in the rabbit. J Clin Invest. 1983;71:487–99.

    PubMed  CAS  Google Scholar 

  31. Border WA, Ward HJ, Kamil ES, et al. Induction of membranous nephropathy in rabbits by administration of an exogenous cationic antigen. J Clin Invest. 1982;69:451–61.

    PubMed  CAS  Google Scholar 

  32. Chen JS, Chen A, Chang LC, et al. Mouse model of membranous nephropathy induced by cationic bovine serum albumin: antigen dose-response relations and strain differences. Nephrol Dial Transplant. 2004;19:2721–8.

    PubMed  CAS  Google Scholar 

  33. Perez-Maceda B, Lopez-Bote JP, Langa C, et al. Antibodies to dietary antigens in rheumatoid arthritis—possible molecular mimicry mechanism. Clin Chim Acta. 1991;203:153–65.

    PubMed  CAS  Google Scholar 

  34. Winer S, Astsaturov I, Cheung RK, et al. T cells of multiple sclerosis patients target a common environmental peptide that causes encephalitis in mice. J Immunol. 2001;166:4751–6.

    PubMed  CAS  Google Scholar 

  35. Feehally J, Farrall M, Boland A, et al. HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol. 2010;21:1791–7.

    PubMed  CAS  Google Scholar 

  36. Gharavi AG, Kiryluk K, Choi M, et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet. 2011;43:321–7.

    PubMed  CAS  Google Scholar 

  37. Kim S, Chin HJ, Na KY, et al. Single nucleotide polymorphisms in the phospholipase A2 receptor gene are associated with genetic susceptibility to idiopathic membranous nephropathy. Nephron Clin Pract. 2011;117:c253–8.

    PubMed  Google Scholar 

  38. Liu YH, Chen CH, Chen SY, et al. Association of phospholipase A2 receptor 1 polymorphisms with idiopathic membranous nephropathy in Chinese patients in Taiwan. J Biomed Sci. 2010;17:81.

    PubMed  Google Scholar 

  39. Bockenhauer D, Debiec H, Sebire N, et al. Familial membranous nephropathy: an X-linked genetic susceptibility? Nephron Clin Pract. 2008;108:c10–5.

    PubMed  CAS  Google Scholar 

  40. Short CD, Feehally J, Gokal R, et al. Familial membranous nephropathy. Br Med J. 1984;289:1500.

    CAS  Google Scholar 

  41. Kiryluk K. Risk alleles in idiopathic membranous nephropathy. N Engl J Med. 2011;364:2072–3. author reply 2073–2074.

    PubMed  CAS  Google Scholar 

  42. Cattran DC. Idiopathic membranous glomerulonephritis. Kidney Int. 2001;59:1983–94.

    PubMed  CAS  Google Scholar 

  43. Glassock RJ. Secondary membranous glomerulonephritis. Nephrol Dial Transplant. 1992;7 Suppl 1:64–71.

    PubMed  Google Scholar 

  44. Lefaucheur C, Stengel B, Nochy D, et al. Membranous nephropathy and cancer: epidemiologic evidence and determinants of high-risk cancer association. Kidney Int. 2006;70:1510–7.

    PubMed  CAS  Google Scholar 

  45. Ponticelli C. Membranous nephropathy. J Nephrol. 2007;20:268–87.

    PubMed  CAS  Google Scholar 

  46. Obana M, Nakanishi K, Sako M, et al. Segmental membranous glomerulonephritis in children: comparison with global membranous glomerulonephritis. Clin J Am Soc Nephrol. 2006;1:723–9.

    PubMed  Google Scholar 

  47. Markowitz GS. Membranous glomerulopathy: emphasis on secondary forms and disease variants. Adv Anat Pathol. 2001;8:119–25.

    PubMed  CAS  Google Scholar 

  48. Yoshimoto K, Yokoyama H, Wada T, et al. Pathologic findings of initial biopsies reflect the outcomes of membranous nephropathy. Kidney Int. 2004;65:148–53.

    PubMed  Google Scholar 

  49. Kuroki A, Shibata T, Honda H, et al. Glomerular and serum IgG subclasses in diffuse proliferative lupus nephritis, membranous lupus nephritis, and idiopathic membranous nephropathy. Intern Med. 2002;41:936–42.

    PubMed  CAS  Google Scholar 

  50. Schieppati A, Mosconi L, Perna A, et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med. 1993;329:85–9.

    PubMed  CAS  Google Scholar 

  51. Ponticelli C, Zucchelli P, Passerini P, et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int. 1995;48:1600–4.

    PubMed  CAS  Google Scholar 

  52. Honkanen E. Survival in idiopathic membranous glomerulonephritis. Clin Nephrol. 1986;25:122–8.

    PubMed  CAS  Google Scholar 

  53. Row PG, Cameron JS, Turner DR, et al. Membranous nephropathy. Long-term follow-up and association with neoplasia. Q J Med. 1975;44:207–39.

    PubMed  CAS  Google Scholar 

  54. MacTier R, Boulton Jones JM, Payton CD, et al. The natural history of membranous nephropathy in the West of Scotland. Q J Med. 1986;60:793–802.

    PubMed  CAS  Google Scholar 

  55. Ponticelli C, Passerini P. Membranous nephropathy. In: Ponticelli C, Glassock RJ, editors. Treatment of primary glomerulonephritis. Oxford: Oxford University Press; 1997. p. 146–85.

    Google Scholar 

  56. Polanco N, Gutierrez E, Covarsi A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol. 2010;21(4):697–704.

    PubMed  CAS  Google Scholar 

  57. Maisonneuve P, Agodoa L, Gellert R, et al. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. Am J Kidney Dis. 2000;35:157–65.

    PubMed  CAS  Google Scholar 

  58. Cattran DC, Reich HN, Kim SJ, et al. Have we changed the outcome in membranous nephropathy? A propensity study on the role of immunosuppressive therapy. Clin J Am Soc Nephrol. 2011;6:1591–8.

    PubMed  Google Scholar 

  59. Cattran D. Management of membranous nephropathy: when and what for treatment. J Am Soc Nephrol. 2005;16:1188–94.

    PubMed  Google Scholar 

  60. Glassock RJ. The treatment of idiopathic membranous nephropathy: a dilemma or a conundrum? Am J Kidney Dis. 2004;44:562–6.

    PubMed  Google Scholar 

  61. Marx BE, Marx M. Prediction in idiopathic membranous nephropathy. Kidney Int. 1999;56:666–73.

    PubMed  CAS  Google Scholar 

  62. Troyanov S, Roasio L, Pandes M, et al. Renal pathology in idiopathic membranous nephropathy: a new perspective. Kidney Int. 2006;69:1641–8.

    PubMed  CAS  Google Scholar 

  63. Reichert LJ, Koene RA, Wetzels JF. Urinary IgG excretion as a prognostic factor in idiopathic membranous nephropathy. Clin Nephrol. 1997;48:79–84.

    PubMed  CAS  Google Scholar 

  64. Reichert LJ, Koene RA, Wetzels JF. Urinary excretion of beta 2-microglobulin predicts renal outcome in patients with idiopathic membranous nephropathy. J Am Soc Nephrol. 1995;6:1666–9.

    PubMed  CAS  Google Scholar 

  65. Branten AJ, du Buf-Vereijken PW, Klasen IS, et al. Urinary excretion of beta2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: a validation study. J Am Soc Nephrol. 2005;16:169–74.

    PubMed  CAS  Google Scholar 

  66. Bakoush O, Torffvit O, Rippe B, et al. Renal function in proteinuric glomerular diseases correlates to the changes in urine IgM excretion but not to the changes in the degree of albuminuria. Clin Nephrol. 2003;59:345–52.

    PubMed  CAS  Google Scholar 

  67. Bazzi C, Petrini C, Rizza V, et al. Urinary excretion of IgG and alpha(1)-microglobulin predicts clinical course better than extent of proteinuria in membranous nephropathy. Am J Kidney Dis. 2001;38:240–8.

    PubMed  CAS  Google Scholar 

  68. van den Brand JA, Hofstra JM, Wetzels JF. Low-molecular-weight proteins as prognostic markers in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2011;6:2846–53.

    PubMed  Google Scholar 

  69. Pei Y, Cattran D, Greenwood C. Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int. 1992;42:960–6.

    PubMed  CAS  Google Scholar 

  70. Cattran DC, Pei Y, Greenwood CM, et al. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int. 1997;51:901–7.

    PubMed  CAS  Google Scholar 

  71. Troyanov SWC, Miller JA, Scholey JW, Cattran DC. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int. 2004;66:1199–205.

    PubMed  Google Scholar 

  72. Ponticelli C, Passerini P, Altieri P, et al. Remissions and relapses in idiopathic membranous nephropathy. Nephrol Dial Transplant. 1992;7 Suppl 1:85–90.

    PubMed  Google Scholar 

  73. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123:754–62.

    PubMed  CAS  Google Scholar 

  74. Giordano M, De Feo P, Lucidi P, et al. Effects of dietary protein restriction on fibrinogen and albumin metabolism in nephrotic patients. Kidney Int. 2001;60:235–42.

    PubMed  CAS  Google Scholar 

  75. Apperloo AJ, de Zeeuw D, de Jong PE. Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int Suppl. 1994;45:S174–8.

    PubMed  CAS  Google Scholar 

  76. Rossing P, Hommel E, Smidt UM, et al. Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kid Int Suppl. 1994;45:S145–149.

    CAS  Google Scholar 

  77. Keane WF, Brenner BM, de Zeeuw D, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int. 2003;63:1499–507.

    PubMed  Google Scholar 

  78. Gansevoort RT, Heeg JE, Vriesendorp R, et al. Antiproteinuric drugs in patients with idiopathic membranous glomerulopathy. Nephrol Dial Transplant. 1992;7 Suppl 1:91–6.

    PubMed  Google Scholar 

  79. Ruggenenti P, Mosconi L, Vendramin G, et al. ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome. Am J Kidney Dis. 2000;35:381–91.

    PubMed  CAS  Google Scholar 

  80. Ambalavanan S, Fauvel JP, Sibley RK, et al. Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy. J Am Soc Nephrol. 1996;7:290–8.

    PubMed  CAS  Google Scholar 

  81. Rostoker G, Ben Maadi A, Remy P, et al. Low-dose angiotensin-converting-enzyme inhibitor captopril to reduce proteinuria in adult idiopathic membranous nephropathy: a prospective study of long-term treatment. Nephrol Dial Transplant. 1995;10:25–9.

    PubMed  CAS  Google Scholar 

  82. du Buf-Vereijken PW, Branten AJ, Wetzels JF. Idiopathic membranous nephropathy: outline and rationale of a treatment strategy. Am J Kidney Dis. 2005;46:1012–29.

    PubMed  Google Scholar 

  83. Praga M, Borstein B, Andres A, et al. Nephrotic proteinuria without hypoalbuminemia: clinical characteristics and response to angiotensin-converting enzyme inhibition. Am J Kidney Dis. 1991;17:330–8.

    PubMed  CAS  Google Scholar 

  84. Praga M, Hernandez E, Montoyo C, et al. Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis. 1992;20:240–8.

    PubMed  CAS  Google Scholar 

  85. Glassock RJ. Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum. J Am Soc Nephrol. 2007;18:2221–5.

    PubMed  Google Scholar 

  86. Black DA, Rose G, Brewer DB. Controlled trial of prednisone in adult patients with the nephrotic syndrome. Br Med J. 1970;3:421–6.

    PubMed  CAS  Google Scholar 

  87. Cattran DC, Delmore T, Roscoe J, et al. A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. N Engl J Med. 1989;320:210–5.

    PubMed  CAS  Google Scholar 

  88. A controlled study of short-term prednisone treatment in adults with membranous nephropathy. Collaborative Study of the Adult Idiopathic Nephrotic Syndrome. N Engl J Med. 1979;301:1301–6.

    Google Scholar 

  89. Cameron JS, Healy MJ, Adu D. The Medical Research Council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. The MRC Glomerulonephritis Working Party. Q J Med. 1990;74:133–56.

    PubMed  CAS  Google Scholar 

  90. Hogan SL, Muller KE, Jennette JC, et al. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis. 1995;25:862–75.

    PubMed  CAS  Google Scholar 

  91. Perna A, Schieppati A, Zamora J, et al. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis. 2004;44:385–401.

    PubMed  Google Scholar 

  92. Mathieson PW. The podocyte as a target for therapies—new and old. Nat Rev Nephrol. 2012;8:52–6.

    CAS  Google Scholar 

  93. Donadio Jr JV, Holley KE, Anderson CF, et al. Controlled trial of cyclophosphamide in idiopathic membranous nephropathy. Kidney Int. 1974;6:431–9.

    PubMed  Google Scholar 

  94. Lagrue G, Bernard D, Bariety J, et al. Traitement par le chlorambucil et l’azathioprine dans les glomerulonephrites primitives. Resultats d’une etude “controlee”. J Urol Nephrol. 1975;81:655–72.

    CAS  Google Scholar 

  95. Tiller DJ, Clarkson AR, Mathew T, Thompson N, Row G, Lauer C, Hobbs J, Seymour A: A prospective randomized trial in the use of cyclophosphamide, dipyridamole and warfarin in membranous and mesangiocapillary glomerulonephritis. Proc 8th Int Congr Nephrol, Athens, Uiversity Studio and Karger, Thessaloniki, 1981 pp 345–351

    Google Scholar 

  96. Murphy BF, McDonald I, Fairley KF, et al. Randomized controlled trial of cyclophosphamide, warfarin and dipyridamole in idiopathic membranous glomerulonephritis. Clin Nephrol. 1992;37:229–34.

    PubMed  CAS  Google Scholar 

  97. Hofstra JM, Wetzels JF. Alkylating agents in membranous nephropathy: efficacy proven beyond doubt. Nephrol Dial Transplant. 2010;25:1760–6.

    PubMed  CAS  Google Scholar 

  98. Ponticelli C, Zucchelli P, Imbasciati E, et al. Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med. 1984;310:946–50.

    PubMed  CAS  Google Scholar 

  99. Ponticelli C, Zucchelli P, Passerini P, et al. Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group. N Engl J Med. 1992;327:599–603.

    PubMed  CAS  Google Scholar 

  100. Ponticelli C, Altieri P, Scolari F, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol. 1998;9:444–50.

    PubMed  CAS  Google Scholar 

  101. Jha V, Ganguli A, Saha TK, et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol. 2007;18:1899–904.

    PubMed  CAS  Google Scholar 

  102. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med. 1981;304:441–7.

    PubMed  CAS  Google Scholar 

  103. Kahn MF, Arlet J, Bloch-Michel H, et al. Acute leukaemias after treatment using cytotoxic agents for rheumatological purpose. 19 cases among 2006 patients (author’s transl). Nouv Presse Med. 1979;8:1393–7.

    PubMed  CAS  Google Scholar 

  104. Kinlen LJ, Sheil AG, Peto J, et al. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J. 1979;2:1461–6.

    PubMed  CAS  Google Scholar 

  105. Wall RL, Clausen KP. Carcinoma of the urinary bladder in patients receiving cyclophosphamide. N Engl J Med. 1975;293:271–3.

    PubMed  CAS  Google Scholar 

  106. Grunwald HW, Rosner F. Acute leukemia and immunosupressive drug use: a review of patients undergoing immunosuppressive therapy for non-neoplastic diseases. Arch Intern Med. 1979;139:461–6.

    PubMed  CAS  Google Scholar 

  107. Smith AG, Prentice AG, Lucie NP, et al. Acute myelogenous leukaemia following cytotoxic therapy: five cases and a review. Q J Med. 1982;51:227–40.

    PubMed  CAS  Google Scholar 

  108. Baltus JA, Boersma JW, Hartman AP, et al. The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up. Ann Rheum Dis. 1983;42:368–73.

    PubMed  CAS  Google Scholar 

  109. Fraumeni JFDS, Hoover RN, Kinlen LJ. Epidemiology of cancer. In: Devita VTHS, Posenberg SA, editors. Cancer principles and practice of oncology. Philadelphia: JB, Lippincott; 1993. p. 150–81.

    Google Scholar 

  110. Howman A, Chapman TL, Langdon MM, et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet. 2013;381(9868):744–51.

    PubMed  CAS  Google Scholar 

  111. De Santo NG, Capodicasa G, Giordano C. Treatment of idiopathic membranous nephropathy unresponsive to methylprednisolone and chlorambucic with cyclosporin A. Am J Nephrol. 1987;7:74–6.

    Google Scholar 

  112. Fritsche L, Budde K, Farber L, et al. Treatment of membranous glomerulopathy with cyclosporin A: how much patience is required? Nephrol Dial Transplant. 1999;14:1036–8.

    PubMed  CAS  Google Scholar 

  113. Goumenos DS, Kalliakmani P, Tsakas S, et al. The remission of nephrotic syndrome with cyclosporin treatment does not attenuate the progression of idiopathic membranous nephropathy. Clin Nephrol. 2004;61:17–24.

    PubMed  CAS  Google Scholar 

  114. Guasch A, Suranyi M, Newton L, et al. Short-term responsiveness of membranous glomerulopathy to cyclosporine. Am J Kidney Dis. 1992;20:472–81.

    PubMed  CAS  Google Scholar 

  115. Meyrier A. Treatment of glomerular disease with cyclosporin A. Nephrol Dial Transplant. 1989;4:923–31.

    PubMed  CAS  Google Scholar 

  116. Rostoker G, Belghiti D, Ben Maadi A, et al. Long-term cyclosporin A therapy for severe idiopathic membranous nephropathy. Nephron. 1993;63:335–41.

    PubMed  CAS  Google Scholar 

  117. Kalliakmani P, Koutroulia E, Sotsiou F, et al. Benefit and cost from the long-term use of cyclosporine-A in idiopathic membranous nephropathy. Nephrology (Carlton). 2010;15:762–7.

    Google Scholar 

  118. Alexopoulos E, Papagianni A, Tsamelashvili M, et al. Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome. Nephrol Dial Transplant. 2006;21:3127–32.

    PubMed  CAS  Google Scholar 

  119. Meyrier A. Antiproteinuric and immunological effects of cyclosporin A in the treatment of glomerular diseases. Nephrol Dial Transplant. 1992;7 Suppl 1:80–4.

    PubMed  Google Scholar 

  120. Cattran DC, Appel GB, Hebert LA, et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int. 2001;59:1484–90.

    PubMed  CAS  Google Scholar 

  121. Ponticelli C, Villa M. Does cyclosporin have a role in the treatment of membranous nephropathy? Nephrol Dial Transplant. 1999;14:23–5.

    PubMed  Google Scholar 

  122. Feutren G, Mihatsch MJ. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N Engl J Med. 1992;326:1654–60.

    PubMed  CAS  Google Scholar 

  123. Cattran DC, Alexopoulos E, Heering P, et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations. Kidney Int. 2007;72:1429–47.

    PubMed  CAS  Google Scholar 

  124. Ballarin J, Poveda R, Ara J, et al. Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil: results of a pilot study. Nephrol Dial Transplant. 2007;22:3196–201.

    PubMed  CAS  Google Scholar 

  125. Praga M, Barrio V, Juarez GF, et al. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 2007;71:924–30.

    PubMed  CAS  Google Scholar 

  126. Berg AL, Nilsson-Ehle P, Arnadottir M. Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy. Kidney Int. 1999;56:1534–43.

    PubMed  CAS  Google Scholar 

  127. Picardi L, Villa G, Galli F, et al. ACTH therapy in nephrotic syndrome induced by idiopathic membranous nephropathy. Clin Nephrol. 2004;62:403–4.

    PubMed  CAS  Google Scholar 

  128. Ponticelli C, Passerini P, Salvadori M, et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis. 2006;47:233–40.

    PubMed  CAS  Google Scholar 

  129. Arnadottir MSB, Berg A-L. A randomized study on treatment with adrenocorticotropic hormone in idiopathic membranous nephropathy. J Am Soc Nephrol. 2006;17:571A.

    Google Scholar 

  130. Bomback AS, Tumlin JA, Baranski J, et al. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel. Drug Des Devel Ther. 2011;5:147–53.

    PubMed  CAS  Google Scholar 

  131. Ghiggeri GM, Bruschi M, Candiano G, et al. Depletion of clusterin in renal diseases causing nephrotic syndrome. Kidney Int. 2002;62:2184–94.

    PubMed  CAS  Google Scholar 

  132. Orlando RA, Kerjaschki D, Farquhar MG. Megalin (gp330) possesses an antigenic epitope capable of inducing passive Heymann nephritis independent of the nephritogenic epitope in receptor-associated protein. J Am Soc Nephrol. 1995;6:61–7.

    PubMed  CAS  Google Scholar 

  133. Lindskog A, Ebefors K, Johansson ME, et al. Melanocortin 1 receptor agonists reduce proteinuria. J Am Soc Nephrol. 2010;21:1290–8.

    PubMed  CAS  Google Scholar 

  134. Schaffer JV, Bolognia JL. The melanocortin-1 receptor: red hair and beyond. Arch Dermatol. 2001;137:1477–85.

    PubMed  CAS  Google Scholar 

  135. Beck Jr LH, Fervenza FC, Bomback AS, Ayalon R, Irazabal MV, Eirin A, Cattran DC, Appel GB, Salant DJ. Response of anti-PLA2R to adrenocorticotropic hormone (ACTH) gel in membranous nephropathy. Proceedings of the American Society of Nephrology Meeting, Philadelphia, PA, 2011.

    Google Scholar 

  136. Bussel A, Boulechfar H, Naim R. Immunoglobulins or plasma exchange? Synchronization of plasma exchange and intravenous polyvalent immunoglobulins. A consecutive study of 11 patients. Ann Med Interne (Paris). 1993;144:532–8.

    CAS  Google Scholar 

  137. Jordan SC, Toyoda M. Treatment of autoimmune diseases and systemic vasculitis with pooled human intravenous immune globulin. Clin Exp Immunol. 1994;97 Suppl 1:31–8.

    PubMed  Google Scholar 

  138. Nangaku M, Pippin J, Richardson CA, et al. Beneficial effects of systemic immunoglobulin in experimental membranous nephropathy. Kidney Int. 1996;50:2054–62.

    PubMed  CAS  Google Scholar 

  139. TKida H, Tomosugi N, Yokoyama H. High-dose gammaglobulin therapy in membranous nephropathy. Proceedings of the 10th International Congress of Nephrology, July 26-31 (abs) London 1987.

    Google Scholar 

  140. Palla R, Cirami C, Panichi V, et al. Intravenous immunoglobulin therapy of membranous nephropathy: efficacy and safety. Clin Nephrol. 1991;35:98–104.

    PubMed  CAS  Google Scholar 

  141. Yokoyama H, Goshima S, Wada T, et al. The short- and long-term outcomes of membranous nephropathy treated with intravenous immune globulin therapy. Kanazawa Study Group for Renal Diseases and Hypertension. Nephrol Dial Transplant. 1999;14:2379–86.

    PubMed  CAS  Google Scholar 

  142. Penny MJ, Boyd RA, Hall BM. Mycophenolate mofetil prevents the induction of active Heymann nephritis: association with Th2 cytokine inhibition. J Am Soc Nephrol. 1998;9:2272–82.

    PubMed  CAS  Google Scholar 

  143. Luca ME, Paul LC, van Der Wal AM, et al. Treatment with mycophenolate mofetil attenuates the development of Heymann nephritis. Exp Nephrol. 2000;8:77–83.

    PubMed  CAS  Google Scholar 

  144. Miller G, Zimmerman III R, Radhakrishnan J, et al. Use of mycophenolate mofetil in resistant membranous nephropathy. Am J Kidney Dis. 2000;36:250–6.

    PubMed  CAS  Google Scholar 

  145. Choi MJ, Eustace JA, Gimenez LF, et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int. 2002;61:1098–114.

    PubMed  CAS  Google Scholar 

  146. Polenakovic M, Grcevska L, Dzikova S. Mycophenolate mofetil in treatment of idiopathic stages III-IV membranous nephropathy. Nephrol Dial Transplant. 2003;18:1233–4.

    PubMed  CAS  Google Scholar 

  147. Branten AJ, du Buf-Vereijken PW, Vervloet M, et al. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis. 2007;50:248–56.

    PubMed  CAS  Google Scholar 

  148. Senthil Nayagam L, Ganguli A, Rathi M, et al. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. Nephrol Dial Transplant. 2008;23:1926–30.

    PubMed  Google Scholar 

  149. Dussol B, Morange S, Burtey S, et al. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. Am J Kidney Dis. 2008;52:699–705.

    PubMed  CAS  Google Scholar 

  150. Kerjaschki D, Neale TJ. Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis). J Am Soc Nephrol. 1996;7:2518–26.

    PubMed  CAS  Google Scholar 

  151. Cupps TR, Edgar LC, Fauci AS. Suppression of human B lymphocyte function by cyclophosphamide. J Immunol. 1982;128:2453–7.

    PubMed  CAS  Google Scholar 

  152. Zhu LP, Cupps TR, Whalen G, et al. Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells. J Clin Invest. 1987;79:1082–90.

    PubMed  CAS  Google Scholar 

  153. Remuzzi G, Chiurchiu C, Abbate M, et al. Rituximab for idiopathic membranous nephropathy. Lancet. 2002;360:923–4.

    PubMed  CAS  Google Scholar 

  154. Ruggenenti P, Chiurchiu C, Abbate M, Perna A, Cradevi P, Bontempelli M, Remuzzi G. Rituximab for idiopathic membranous nephropathy: who can benefit? Clin J Am Soc Nephrol. 2006;1:738–48.

    PubMed  CAS  Google Scholar 

  155. Fervenza FC, Abraham RS, Erickson SB, et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol. 2010;5:2188–98.

    PubMed  CAS  Google Scholar 

  156. Fervenza FC, Cosio FG, Erickson SB, et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. 2008;73:117–25.

    PubMed  CAS  Google Scholar 

  157. Cravedi P, Ruggenenti P, Sghirlanzoni MC, et al. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2007;2:932–7.

    PubMed  CAS  Google Scholar 

  158. Cravedi P, Sghirlanzoni MC, Marasa M, et al. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study. Am J Nephrol. 2011;33:461–8.

    PubMed  CAS  Google Scholar 

  159. Ruggenenti P, Cravedi P, Chianca A, et al. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol. 2012;23:1416–25.

    PubMed  CAS  Google Scholar 

  160. Segarra A, Praga M, Ramos N, et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin J Am Soc Nephrol. 2009;4:1083–8.

    PubMed  CAS  Google Scholar 

  161. Hoxha E, Harendza S, Zahner G, et al. An immunofluorescence test for phospholipase-A-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant. 2011;26:2526–32.

    PubMed  CAS  Google Scholar 

  162. Appel GNP, Hogan S, Radhakrishnan J, Old C, Hebert L, Fervenza F, Kumor K, Petro B, Li L, Hardman J. Eculizumab (C5 complement inhibitor) in the treatment of idiopathic membranous nephropathy (abstract). J Am Soc Nephrol. 2002;13:668A.

    Google Scholar 

  163. Short CD, Solomon LR, Gokal R, et al. Methylprednisolone in patients with membranous nephropathy and declining renal function. Q J Med. 1987;65:929–40.

    PubMed  CAS  Google Scholar 

  164. Mathieson PW, Turner AN, Maidment CG, et al. Prednisolone and chlorambucil treatment in idiopathic membranous nephropathy with deteriorating renal function. Lancet. 1988;2:869–72.

    PubMed  CAS  Google Scholar 

  165. Wetzels JFM, Hoitsma A, Koene RAP. Immunosuppression for membranous nephropathy. Lancet. 1989;1:211 (letter).

    Google Scholar 

  166. Araque A, Mazuecos A, Andrés A, Sanchez R, Ortuňo T, Praga M. Tratamiento con esteroides y clorambucil de las glomerulonefritis membranosas idiopaticas con insuficiencia renal progresiva. Nefrologia. 1993;4:350–5.

    Google Scholar 

  167. Warwick GL, Geddes CG, Boulton-Jones JM. Prednisolone and chlorambucil therapy for idiopathic membranous nephropathy with progressive renal failure. Q J Med. 1994;87:223–9.

    PubMed  CAS  Google Scholar 

  168. Brunkhorst R, Wrenger E, Koch KM. Low-dose prednisolone/chlorambucil therapy in patients with severe membranous glomerulonephritis. Clin Invest. 1994;72:277–82.

    CAS  Google Scholar 

  169. Stirling CM, Simpson K, Boulton-Jones JM. Immunosuppression and outcome in idiopathic membranous nephropathy. QJM. 1998;91:159–64.

    PubMed  CAS  Google Scholar 

  170. Torres A, Dominguez-Gil B, Carreno A, et al. Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. Kidney Int. 2002;61:219–27.

    PubMed  CAS  Google Scholar 

  171. Bruns FJ, Adler S, Fraley DS, et al. Sustained remission of membranous glomerulonephritis after cyclophosphamide and prednisone. Ann Intern Med. 1991;114:725–30.

    PubMed  CAS  Google Scholar 

  172. Jindal K, West M, Bear R, et al. Long-term benefits of therapy with cyclophosphamide and prednisone in patients with membranous glomerulonephritis and impaired renal function. Am J Kidney Dis. 1992;19:61–7.

    PubMed  CAS  Google Scholar 

  173. Branten AJ, Wetzels JF. Short- and long-term efficacy of oral cyclophosphamide and steroids in patients with membranous nephropathy and renal insufficiency. Study Group. Clin Nephrol. 2001;56:1–9.

    PubMed  CAS  Google Scholar 

  174. du Buf-Vereijken PW, Wetzels JF. Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity. Nephrol Dial Transplant. 2004;19:2036–43.

    PubMed  Google Scholar 

  175. Falk RJ, Hogan SL, Muller KE, et al. Treatment of progressive membranous glomerulopathy. A randomized trial comparing cyclophosphamide and corticosteroids with corticosteroids alone. The Glomerular Disease Collaborative Network. Ann Intern Med. 1992;116:438–45.

    PubMed  CAS  Google Scholar 

  176. Reichert LJ, Huysmans FT, Assmann K, et al. Preserving renal function in patients with membranous nephropathy: daily oral chlorambucil compared with intermittent monthly pulses of cyclophosphamide. Ann Intern Med. 1994;121:328–33.

    PubMed  CAS  Google Scholar 

  177. Cattran DC, Greenwood C, Ritchie S, et al. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group. Kidney Int. 1995;47:1130–5.

    PubMed  CAS  Google Scholar 

  178. Richter P, Calamera JC, Morgenfeld MC, et al. Effect of chlorambucil on spermatogenesis in the human with malignant lymphoma. Cancer. 1970;25:1026–30.

    PubMed  CAS  Google Scholar 

  179. Ponticelli C. Prognosis and treatment of membranous nephropathy. Kidney Int. 1986;29:927–40.

    PubMed  CAS  Google Scholar 

  180. Diaz-Buxo JA, Donadio Jr JV. Complications of percutaneous renal biopsy: an analysis of 1,000 consecutive biopsies. Clin Nephrol. 1975;4:223–7.

    PubMed  CAS  Google Scholar 

  181. Goodwin JS, Searles RP, Tung KS. Immunological responses of healthy elderly population. Clin Exp Immunol. 1982;48:403–10.

    PubMed  CAS  Google Scholar 

  182. Moorthy AV, Zimmerman SW. Renal disease in the elderly: clinicopathologic analysis of renal disease in 115 elderly patients. Clin Nephrol. 1980;14:223–9.

    PubMed  CAS  Google Scholar 

  183. Moran D, Korzets Z, Bernheim J, et al. Is renal biopsy justified for the diagnosis and management of the nephrotic syndrome in the elderly? Gerontology. 1993;39:49–54.

    PubMed  CAS  Google Scholar 

  184. Moulin B, Dhib M, Sommervogel C, et al. Value of renal biopsy in the elderly. 32 cases. Presse Med. 1991;20:1881–5.

    PubMed  CAS  Google Scholar 

  185. Rossen RD, Reisberg MA, Singer D, et al. The effect of age on the character of immune complex disease: a comparison of the incidence and relative size of materials reactive with Clq in sera of patients with glomerulonephritis and cancer. Medicine. 1979;58:65–79.

    PubMed  CAS  Google Scholar 

  186. Zent R, Nagai R, Cattran DC. Idiopathic membranous nephropathy in the elderly: a comparative study. Am J Kidney Dis. 1997;29:200–6.

    PubMed  CAS  Google Scholar 

  187. Davison AM, Johnston PA. Idiopathic glomerulonephritis in the elderly. Contrib Nephrol. 1993;105:38–48.

    PubMed  CAS  Google Scholar 

  188. Donadio Jr JV. Treatment of glomerulonephritis in the elderly. Am J kidney Dis. 1990;16:307–11.

    PubMed  Google Scholar 

  189. O’Callaghan CA, Hicks J, Doll H, et al. Characteristics and outcome of membranous nephropathy in older patients. Int Urol Nephrol. 2002;33:157–65.

    PubMed  Google Scholar 

  190. Bolton WK. Nephrotic syndrome in the aged. In: Cameron JS, Glassoc RK, editors. The nephrotic syndrome. New York: Dekker; 1988. p. 523–53.

    Google Scholar 

  191. Lustig S, Rosenfeld JB, Ben-Bassat M, et al. Nephrotic syndrome in the elderly. Isr J Med Sci. 1982;18:1010–3.

    PubMed  CAS  Google Scholar 

  192. Zech P, Colon S, Pointet P, et al. The nephrotic syndrome in adults aged over 60: etiology, evolution and treatment of 76 cases. Clin Nephrol. 1982;17:232–6.

    PubMed  CAS  Google Scholar 

  193. Passerini P, Como G, Vigano E, et al. Idiopathic membranous nephropathy in the elderly. Nephrol Dial Transplant. 1993;8:1321–5.

    PubMed  CAS  Google Scholar 

  194. Rollino C, Roccatello D, Vallero A, Basolo B, Piccoli G. Membranous glomerulonephritis in the elderly. Is treatment still worthwhile? Geriatr Nephrol Urol. 1995;5:97–104.

    Google Scholar 

  195. Sakemi T, Yamaguchi M, Fujimi S, et al. Effects of the methylprednisolone pulse therapy on renal function. Am J Nephrol. 1991;11:48–53.

    PubMed  CAS  Google Scholar 

  196. Ueda N, Yoshikawa T, Chihara M, et al. Atrial fibrillation following methylprednisolone pulse therapy. Pediatr Nephrol. 1988;2:29–31.

    PubMed  CAS  Google Scholar 

  197. Ponticelli C, Glassock RJ. Posttransplant recurrence of primary glomerulonephritis. Clin J Am Soc Nephrol. 2010;5:2363–72.

    PubMed  Google Scholar 

  198. Dabade TS, Grande JP, Norby SM, et al. Recurrent idiopathic membranous nephropathy after kidney transplantation: a surveillance biopsy study. Am J Transplant. 2008;8:1318–22.

    PubMed  CAS  Google Scholar 

  199. Moroni G, Gallelli B, Quaglini S, et al. Long-term outcome of renal transplantation in patients with idiopathic membranous glomerulonephritis (MN). Nephrol Dial Transplant. 2010;25:3408–15.

    PubMed  Google Scholar 

  200. Debiec H, Martin L, Jouanneau C, et al. Autoantibodies specific for the phospholipase A2 receptor in recurrent and De Novo membranous nephropathy. Am J Transplant. 2011;11:2144–52.

    PubMed  CAS  Google Scholar 

  201. El-Zoghby ZM, Grande JP, Fraile MG, et al. Recurrent idiopathic membranous nephropathy: early diagnosis by protocol biopsies and treatment with anti-CD20 monoclonal antibodies. Am J Transplant. 2009;9:2800–7.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA

    Fernando C. Fervenza M.D., Ph.D.

  2. Division of Nephrology and Dialysis, Fondazione IRCCS Ca Grande Ospediale Maggiore Policlinico, Milan, Italy

    Patrizia Passerini M.D.

  3. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

    Sanjeev Sethi M.D., Ph.D.

  4. Division of Nephrology, Humanitas, Rozzano, Milano, Italy

    Claudio Ponticelli M.D.

Authors
  1. Fernando C. Fervenza M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrizia Passerini M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sanjeev Sethi M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Claudio Ponticelli M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fernando C. Fervenza M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Div. Nephrology & Hypertension, Mayo Clinic Dept. Internal Medicine, Rochester, Minnesota, USA

    Fernando C. Fervenza

  2. Renal Division, Brigham and Women's Hospital, Boston, Massachusetts, USA

    Julie Lin

  3. Mayo Clinic, Rochester, Minnesota, USA

    Sanjeev Sethi

  4. Renal Division, Brigham and Women's Hospital Harvard Medical School, Boston, Massachusetts, USA

    Ajay K. Singh

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Fervenza, F.C., Passerini, P., Sethi, S., Ponticelli, C. (2014). Membranous Nephropathy. In: Fervenza, F., Lin, J., Sethi, S., Singh, A. (eds) Core Concepts in Parenchymal Kidney Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8166-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-8166-9_5

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-8165-2

  • Online ISBN: 978-1-4614-8166-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation